Cancer Drug Developers Secure Regulatory Clarity as FDA Reshapes Approval Standards [Canadian Business Journal (Canada)]
Oncolytics Biotech Inc. - Common Shares (ONCY)
Last oncolytics biotech inc. - common shares earnings: 11/12 04:00 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.oncolyticsbiotech.com
Company Research
Source: Canadian Business Journal
VANCOUVER, British Columbia, Dec. 16, 2025 (GLOBE NEWSWIRE) —Equity-Insider.comNews Commentary[1][2]Oncolytics Biotech Inc.Immunome, Inc.Prelude Therapeutics IncorporatedContext Therapeutics Inc.Relay Therapeutics, Inc.announced promising efficacy and translational dataThe data strengthen pelareorep’s potential across gastrointestinal tumors, building on recentanal cancer resultsTranslational analysis revealed that pelareorep treatment led to notable increases in KRAS-mutant-specific T-cell populations, providing mechanistic support for the clinical activity observed in this genetically defined patient population. These findings position pelareorep as a precision immunotherapy capable of providing a meaningful clinical benefit over the current standard of care.“Colorectal cancer is the core of our emerging GI tumor platform strategy for pelareorep, with a projected total addressable market of $20 billion by 2033,” said Jared Kelly, CEO ofThe company plans to sponsor a controlled study
Show less
Read more
Impact Snapshot
Event Time:
ONCY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ONCY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ONCY alerts
High impacting Oncolytics Biotech Inc. - Common Shares news events
Weekly update
A roundup of the hottest topics
ONCY
News
- Cancer Drug Developers Secure Regulatory Clarity as FDA Reshapes Approval StandardsGlobeNewswire
- Oncolytics Biotech® Announces Promising Efficacy and Translational Data Supporting Pelareorep in KRAS-Mutant Metastatic Colorectal CancerBusiness Wire
- THE VISIBILITY INDEX: 5 Companies Solving the Invisible Crisis [Canadian Business Journal (Canada)]Canadian Business Journal
- THE VISIBILITY INDEX: 5 Companies Solving the Invisible CrisisGlobeNewswire
- GI Cancer Immunotherapy Breakthroughs Signal New Treatment Era [Canadian Business Journal (Canada)]Canadian Business Journal
ONCY
Earnings
- 11/12/25 - Miss
ONCY
Sec Filings
- 12/16/25 - Form 6-K
- 12/10/25 - Form EFFECT
- 12/10/25 - Form 6-K
- ONCY's page on the SEC website